肝细胞癌的相关血清标志物

HCC的早期诊断是其治疗的关键，HCC血清标志物的检测又为其诊断提供了有利的途径，并且操作简单，敏感性高和特异性强。目前常用的血清标志物为AFP、AFP变异体、AFP mRNA、AFU、GGT、DCP、AIF、GPC3等。这些标志物的联合使用有助于HCC的诊断及预后。     

血半胱氨酸蛋白酶抑制剂C水平对急性脑血管病患者早期肾损害的诊断价值

目的探讨急性脑血管病患者早期肾损害的机制及早期监测指标。方法对194例急性脑血管病患者(包括脑梗死129例,脑出血65例)及60例正常对照者同时测定血半胱氨酸蛋白酶抑制剂C(Cys-C)和血肌酐(SCr)浓度,对其中血Cys-c浓度增高但SCr浓度正常的48例急性脑血管病肾早期损害患者用甘露醇治疗,并检测治疗前后血Cys-c浓度。结果在早期肾损害组,血Cys-c浓度明显高于对照组(P<0.001),而SCr浓度2组无显著性差异(P>0.05)。48例急性脑血管病肾早期损害者经甘露醇治疗后,血Cys-c浓度较治疗前明显降低(P<0.001)。结论血清Cys-c测定有助于早期发现肾功能损害,治疗脑血管病的同时应注意监测肾功能。     

可溶性细胞间黏附分子-1在急性肝内胆汁淤积兔模型中的表达

目的探讨可溶性细胞间黏附分子(sICAM-1)在急性肝内胆汁淤积兔模型中的表达及其意义。方法39只健康的新生大耳白兔随机分成4组:3个实验组(n=9)和1个空白对照组(n=12)。每个实验组分别为3个时间点处理组(24、48、72 h)。实验组采用1次灌服α-荼异硫氰酸盐(ANIT)200 mg/kg方法造成急性肝内胆汁淤积。按时分批取标本,检测其血清和胆汁中sICAM-1水平。结果实验组血清、胆汁中sICAM-1各时间点水平明显高于正常对照组(P均<0.05),其中48 h>72 h>24 h。结论sICAM-1在胆汁淤积中表达升高,与肝脏损伤程度和病程相关。     

脐血胆红素与新生儿黄疸的关系

对海拔1,100米地域出生的144例新生儿,进行了脐血胆红素及新生儿黄疸的研究。脐血胆红素与血清胆红素间差异非常显著(P<0.001)。生后4日内所有新生儿均出现了黄疸。脐血胆红素水平愈高,黄疸出现得愈早(P<0.001)。新生儿重症黄疸(血清胆红素≥205μmol/L)显然与脐血胆红素水平(≥40μtmol/L)有关(P<0.005)。以脐血胆红素预测新生儿重症黄疸,其敏感性为64.7%,特异性为75.6%。     

血清和精浆抑制素B在无精子症诊断中的应用研究

目的:评价血清和精浆抑制素B浓度在诊断梗阻性和非梗阻性无精子症中的应用价值。方法:测定25例正常生育者(正常对照组),37例梗阻性无精子症以及33例非梗阻性无精子症者的血清卵泡刺激素(FSH)、血清和精浆抑制素B浓度,对无精子症者行睾丸病理Johnsen评分。结果:精浆和血清抑制素B浓度比值在正常对照组和非梗阻性无精子组分别为2.17和3.63,差异无显著性(P=0.29);在梗阻性无精子症组两者比值为0.18,与正常对照组和非梗阻性无精子症组比较显著降低(P<0.01)。结论:精浆和血清抑制素B浓度比值可用于临床诊断梗阻性和非梗阻性无精子症。     

高效液相色谱法同时测定兔血清中普罗帕酮和奎尼丁的浓度

目的 :建立高效液相色谱法同时测定家兔血清普罗帕酮和奎尼丁的浓度。方法 :应用YWG -C18(5mm×150mm) ,流动相为甲醇 :醋酸钠 -醋酸缓冲液 :二乙胺 :水 (70 :24.5:0.5:5) ,紫外波长254nm检测。结果 :普罗帕酮、奎尼丁平均回收率分别为99.1 % ,97.9 % ,日内日间精密度分别为 (2.2～3.9) %,(2.6～4.4) %。结论 :方法简单、灵敏、准确 ,可用于临床治疗药物监测。     

五种生物基质对鼠乳腺肿瘤细胞生长和克隆形成的影响

本文研究结果表明,应用无血清培养体系对鼠中孕期乳腺组织细胞(COMMA-1D细胞)、鼠乳腺肿瘤细胞(FUKU细胞)以及CD8F1细胞的原代培养中。BM Matrigel是一良好的细胞附着和细胞生长的促进剂,而Ⅳ型胶原、昆布胺酸和Vitrogen 100对上述细胞的附着和生长也有一定的作用。BM Matrigel和昆布胺酸对FUKU细胞的克隆产率也有显著的促进作用,而昆布胺酸应用方便,价格较低,更适于在实验研究中推广应用。     

Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.

Phospholipidosis (PLD) is characterized by an intracellular accumulation of phospholipids in lysosomes and the concurrent development of concentric lamellar bodies. Recently, H. Sawada et al. (2005, Toxicol. Sci. 83, 282-292) identified 17 genes as potential biomarkers of PLD in HepG2 cells. The present study was undertaken to determine if this set of genes measured by quantitative PCR could be validated in the same cell line. The objective was also to investigate the dose-response relationship to further validate the assay and to select the concentrations to use for screening activities. In a first experiment (one concentration tested), out of the 17 genes, the best gene biomarkers of PLD (i.e., 11 genes) were selected for practical screening reasons. Based on these genes, 91.6% (i.e., 11 of 12) of the compounds known to induce PLD were identified as positive and all the negative compounds (i.e., five of five) were also confirmed. When the data obtained in the first experiment were compared to the data by Sawada et al., (2005) the coefficient of correlation calculated was slightly higher than 75%. In the second experiment (26 compounds [all 17 compounds from the first experiment plus 9 other compounds] tested at a minimum of three concentrations), 93.3% (14/15) of the compounds known to induce PLD were identified as such and all the negative controls (six compounds) were also confirmed. Three compounds likely to induce PLD were identified as positive in our assay. Finally, two compounds for which no data are available were also tested. When both experiments 1 and 2 were compared, the coefficient of correlation for 16 compounds tested at the same concentrations reached 87.7%. In conclusion, the present study further confirms the utility of gene expression in HepG2 cells to identify a potential to induce PLD. Finally, based on the data presented, researchers are encouraged to use a range of minimum three concentrations (e.g., 12.5, 25, and 50 microM) to screen for PLD in the human HepG2 cell line.     

地高辛的体内分析方法应用与进展

目的总结地高辛血药质量浓度监测方法,寻求最适的测定方法。方法对近年来国内外与地高辛监测相关的文献进行检索综述分析。结果地高辛血药浓度测定方法很多,常用方法主要有:FPIA、酶免疫分析法、RIA、CLIA、乳胶免疫抑制法、干化学法、HPLC法等。结论通过比较分析其中RIA、CLIA、EIA和HPLC MS 4种方法更好。     

Is chronic inflammatory change in the prostate the major cause of rising serum prostate‐specific antigen in patients with clinical suspicion of prostate cancer?

AIM: To evaluate the cause of elevated prostate-specific antigen (PSA) in patients with transrectal needle biopsy negative for prostate cancer. METHODS: Serum PSA concentration, prostate volume, and pathologic findings were examined in 223 patients with negative biopsy for prostate cancer. The degree of prostate inflammation was determined by the extent and degree of inflammation shown by biopsy specimens and is expressed as an inflammation score (range: 0-36). RESULTS: A significant correlation was found between PSA concentration and prostate total volume (P=0.0001). Prostate chronic inflammation showed no correlation with PSA concentration (P=0.485, F=0.488). After allocating patients to normal PSA (4 ng/mL) groups, we found that serum PSA concentrations in both groups were predominantly affected by prostate total volume. CONCLUSIONS: An increase in prostate volume appears to be the major contributor to a high serum PSA concentration in patients with negative biopsy for prostate cancer. However, in contrast to previous reports, there was no correlation between the degree of prostate chronic inflammation and serum PSA concentrations.